Skip to main content
Yifeng Pharmacy Chain Co., Ltd. logo

Yifeng Pharmacy Chain Co., Ltd. — Investor Relations & Filings

Ticker · 603939 ISIN · CNE100001TS5 LEI · 300300CZZIF44N1EZO06 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,865 across all filing types
Latest filing 2026-05-26 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603939

About Yifeng Pharmacy Chain Co., Ltd.

https://www.yfdyf.cn/

Yifeng Pharmacy Chain Co., Ltd. operates as a large-scale retail pharmacy enterprise. The company specializes in the distribution and sale of prescription drugs, over-the-counter medicines, traditional Chinese medicine, nutritional supplements, and medical devices. It utilizes a standardized management system across its extensive network of retail stores to ensure service quality and operational efficiency. Beyond physical retail, the company has developed a comprehensive digital healthcare ecosystem, integrating online-to-offline (O2O) services to provide professional pharmaceutical consultations and health management solutions. Its business model focuses on a "big health" strategy, aiming to provide accessible healthcare products and professional services to a broad consumer base through optimized supply chain logistics and a diversified product portfolio.

Recent filings

Filing Released Lang Actions
益丰药房关于不向下修正“益丰转债”转股价格的公告
Capital/Financing Update Classification · 92% confidence The document is a corporate disclosure by Yifeng Pharmacy regarding its convertible bond (“益丰转债”) conversion price adjustment mechanism. It details board resolutions, bond issuance terms, and the decision not to downward adjust the conversion price. This relates to the company’s financing instruments and capital structure rather than routine financial results or management changes. Hence it is classified as a Capital/Financing Update (CAP).
2026-05-26 Chinese
益丰药房第五届董事会第三十次会议决议公告
Regulatory Filings Classification · 75% confidence The document is an announcement of the board of directors’ resolution from the company’s 30th board meeting (fifth session). It does not report a change in board composition or management, nor does it present financial statements or other specialized content (e.g., earnings, M&A, dividends). There is no substantive financial data or executive change disclosed—this is essentially a routine board meeting resolution announcement. It thus falls under the general regulatory/disclosure category rather than a specific report type. Therefore, the correct classification is RNS (Regulatory Filings).
2026-05-26 Chinese
益丰药房2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is the official announcement of resolutions and detailed voting results from the 2025 Annual General Meeting of shareholders, including proposals considered and votes cast. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement.
2026-05-22 Chinese
益丰药房关于2025年年度暨2026年第一季度业绩说明会的公告
Investor Presentation Classification · 91% confidence The document is an announcement by Yifeng Pharmacy Chain Co., Ltd. about scheduling a 2025 annual and 2026 first-quarter performance briefing (业绩说明会) with details on date, format, venue, participants, and Q&A procedures. This is clearly a notice of an upcoming investor presentation rather than the publication of a report itself. Therefore, it falls under the 'Investor Presentation' category (IP).
2026-05-15 Chinese
公司章程（2026年5月修订）
Governance Information Classification · 95% confidence The document is the full text of the company’s articles of association (“公司章程”), setting out the internal rules, governance structures, shareholder rights, board/committee composition, meeting procedures and related matters. It is not an announcement or publication notice, nor a financial report or proxy statement, but rather the governing charter itself. Therefore, it falls squarely under Governance Information (CGR).
2026-05-14 Chinese
益丰药房关于使用闲置募集资金进行现金管理到期赎回的公告
Regulatory Filings Classification · 75% confidence The document is a public announcement detailing the company’s use of idle IPO proceeds (“募集资金”) for cash management (structured deposits), including amounts invested and yields. This is a routine regulatory disclosure in the Chinese market on the use of raised funds rather than a financial report (10-K/IR), dividend notice, share transaction, or other specific categories. It does not constitute an annual or interim report, dividend announcement, share issuance, or management change. Therefore, it falls under the general “Regulatory Filings” category (RNS).
2026-05-14 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.